A critical review of therapeutic interventions in sickle cell disease: progress and challenges.

Ala C, et al. Arch Pharm (Weinheim). 2024;357(11):e2400381

Advances in pharmacotherapy for sickle cell disease: what is the current state of play?

Alan S, Kanter J. Expert Opin Pharmacother. 2024;25(10):1325-1334.

Current state of gene therapy in sickle cell disease.

Tang MS, Shan H. Vox Sang. 2024;119(6):521-528.

A standardized metric to define a successful transition from pediatric to adult care in sickle cell disease.

Pollock G, Curtis S. Blood Adv. 2025;9(18):4622-4623.

Psychosocial challenges of persons with sickle cell anemia: a narrative review.

Essien EA, et al. Medicine (Baltimore). 2023;102(47):e36147.

One-year safety and efficacy of mitapivat in sickle cell disease: follow-up results of a phase 2, open-label study.

van Dijk MJ, et al. Blood Adv. 2023;7(24):7539-7550.

Safety and efficacy of mitapivat in sickle cell disease (RISE UP): results from the phase 2 portion of a global, double-blind, randomized, placebo-controlled trial.

Idowu M, et al. Lancet Haematol. 2025;12(1):e35-e44.

Multicenter, phase 1 study of etavopivat (FT-4202) treatment for up to 12 weeks in patients with sickle cell disease.

Saraf SL, et al. Blood Adv. 2024;8(16):4459-4475.

Etavopivat reduces incidence of vaso-occlusive crises in patients with sickle cell disease: HIBISCUS trial phase 2 results through 52 weeks.

Delicou S, et al. Blood. 2024;144 (suppl 1):179.

PATIENT RESOURCES & ADVOCACY ORGANIZATIONS

Sickle Cell Speaks

Be the Spark

The Foundation for Sickle Cell Disease Research

Sickle Cell Disease Association of America

The Sickle Cell Consortium

Sickle Cell 101

The William E. Proudford Sickle Cell Fund, Inc.

The Foundation for Sickle Cell Disease Research